Background: TransCelerate's model approach to risk-based monitoring (RBM) includes the application of the appropriate monitoring activities to enable both the early detection and timely resolution of issues. This article is a follow-up to part 1, published in the September 2014 issue with the same title. Methods: The intent of this paper is to share information on what has been learned by various companies' applications of central monitoring activities based on different RBM operating models. A library of risk indicators has been created, and this paper provides additional guidance on what has been learned in the application of these tools. Results: The goal is to share the needs related to people, process, and technology as experienced by TransCelerate member companies. Conclusions: One of the primary issue detection methods of central monitoring is the proactive identification of areas of focus through the use of risk indicators.
Introduction
The purpose of monitoring in the context of clinical trials is to ensure that the rights and well-being of human subjects are protected; trial data are accurate, complete, and verifiable; and the study is compliant with the protocol, Good Clinical Practice (GCP), and relevant regulatory requirements. 1 Historically, monitoring was accomplished primarily through on-site monitoring, an approach that typically includes having an individual (a monitor) physically visit a site at predefined intervals and devote the majority of his/her time and effort to source data verification (SDV). 2 Application of a monitoring strategy that best aligns with the risks of a particular trial seeks to ensure earlier detection of issues, with a greater focus on resolution and prevention of issue recurrence. TransCelerate recommends the inclusion of central and off-site monitoring, in addition to on-site monitoring activities, as important components of a well-defined monitoring strategy that is focused on study-specific critical data and processes. 3, 4 As described by TransCelerate, 4 central monitoring is a holistic and ongoing review of operational and clinical data at the program, protocol, country, and site levels that identifies issues and emerging risks. A robust central monitoring strategy involves multifunctional reviews focused on, but not limited to, data management, medical and safety monitoring, and statistics. Table 1 includes definitions from the original TransCelerate publication for risk-based monitoring, 3 as well as the term risk indicator.
Central monitoring activities rely on the skills of people, well-defined processes, and technologies that enable the translation of data into information, and resulting actions and decisions.
This shift in focus regarding monitoring strategy is intended to result in better outcomes for institutions that sponsor clinical trials, for sites that participate in clinical trials, and for patients who generously volunteer their time and information. [6] [7] [8] Two years after the publication of the TransCelerate position paper on risk-based monitoring (RBM), 3 we wanted to examine how the TransCelerate member companies have incorporated central monitoring activities into their monitoring strategies. In part 1 of the central monitoring paper, 4 we shared proposals for how to implement central monitoring. The intent of this second manuscript is to share lessons learned through the application of the various central monitoring models employed by Trans-Celerate member companies during early implementation of RBM methodologies.
Methods
Two surveys of TransCelerate member companies (N ¼ 18) were conducted in order to ascertain best practices associated with central monitoring. The initial survey, distributed in the fourth quarter of 2014, collected information on risk indicators in use and associated benefits. The intent was to establish a risk indicator library 9 (Appendix 1, available as an online supplement, displays just the parameters of the full library). A second survey, conducted in the second quarter of 2015, focused on information (primarily about people and processes) related to central monitoring methods and capabilities (Appendix 2, available online). The second survey included 31 questions covering the following categories: 
Results
The risk indicator survey received responses from 12 of 18 member companies. The second survey received anonymous responses from all 18 contacted member companies, although not all companies answered all of the questions. Within each company, feedback was provided by personnel from a variety of functions, including central monitoring, RBM, data management, clinical operations, statistics, and compliance. The results from both surveys were separated into those related to people and those related to process, and they include some technology considerations.
People
The breakdown of how companies operationally aligned RBM is described in Figure 1 . Thirteen (72%) companies reported making changes to the way they review data based on RBM. Eight (62%) of these 13 companies had some dedicated staff for this activity.
Skill sets or core competencies essential for the central monitor role included communication, leadership, and those skills underpinned by knowledge/experience of site operations and data management. Furthermore, several companies cited the importance of understanding the assessment and management of risks, including the ability to apply analytics for aggregated data and interpret risk indicators to evaluate site performance and data quality.
Individuals performing central monitoring were most often recruited from internal departments (8 of 12 companies) and included people with experience in clinical operations, data management, statistics, quality, and systems support. The survey collected recruitment information via free text, so multiple selections were possible; a total of 8 companies provided additional details indicating multiple departments. For these 8 companies, the most common internal referral source was clinical operations (7 companies), with data management a close second (5 companies). For the 12 companies that answered the question, desirable educational backgrounds for people conducting central monitoring activities included advanced (7 companies) and bachelor's (5 companies) degrees. For most respondents (6 of 9), the qualification expectations have not changed as a result of implementation experience.
Process
The library of risk indicators collected from the initial survey includes more than 175 unique measures. 9 Risk indicator parameters were captured across 9 categories and are detailed in Appendix 1.
Overall, 12 companies submitted a median of 24 (11 to 41) risk indicators to the library. For any given trial, 4 companies reported using more than 26 risk indicators whereas 2 companies used less than 10. A median of 17.5 (10 to 28) core risk indicators were defined as applicable across studies. A median Table 1 . Definitions of Terms.
Term Definition
Central monitoring A ''remote evaluation carried out by sponsor personnel or representatives (e.g., Data Manager, Statistician, or Monitor).'' (FDA Draft Guidance) Off-site monitoring Monitoring activities as defined either within process documents or in the monitoring plan (MP) that occur away from the study site location (eg, at a Monitor's home or in a sponsor representative's office). This is also commonly known as remote monitoring. On-site monitoring ''An in-person evaluation carried out by sponsor personnel or representative(s) at the site(s) at which the clinical investigation is being conducted.'' (FDA Draft Guidance)
Risk indicator
Risk indicators are metrics used to monitor identified risk exposures over time. 5 of 3 (0 to 24) risk indicators represented specific risk indicators limited to specific protocols or programs. Most companies (9 of 12) indicated that they have not identified an optimal number of risk indicators. Companies reported having greater than 1 year of experience with approximately half (50.3%) of the risk indicators. The value of each risk indicator was assessed as high value, neutral, no value, or cannot assess. Figure 2 illustrates the number of risk indicators per category, separated by core versus specific and colored by relative value. For example, 35 total risk indicators for data quality were collected; 32 risk indicators were core (44% of the 32 were considered high value) and 3 were specific. Risk indicators were most commonly assessed cumulatively as opposed to by interval (a subset of data for a given period of time) or both by interval and cumulatively. Although a variety of thresholds were used, almost one-third of the risk indicators were based on static, ordinal thresholds (as opposed to dynamic and/or statistical thresholds). An example of a static ordinal threshold is a query response rate greater than X weeks, which may indicate an unresponsive site.
When questioned about the 5 most important risk indicators, 12 companies provided a range of responses. Adverse events and data flow were consistently important across most companies. Close scrutiny of adverse events (including serious) by way of visualizations and event rate review was indicated by 10 companies, and the evaluation of data flow in terms of delay to data entry was referenced by 9 companies as important. The remaining responses included, but were not limited to, protocol deviation rates, treatment compliance, and additional data quality metrics such as query rates.
Among the 10 companies who expressed a preference regarding the development of future risk indicators, common themes included having risk indicators that could point to data integrity and trial misconduct; the ability to aggregate risk at different levels such as country, region, and trial; and more sophisticated analytics that blend existing risk indicators to improve insight.
Across the 12 respondent companies, the methods by which risk indicators were analyzed and/or visualized varied. The approaches included risk weighting, pattern recognition, scatter plots, and z scores. The most popular method, used by 10 of 12 companies, was the use of risk ratings (low, medium, high).
Various frequencies of risk indicator review were used by 12 companies, with some companies using more than one frequency of review depending on the risk indicator. These included quarterly (n ¼ 2), monthly (n ¼ 6), weekly (n ¼ 5), daily (n ¼ 1), and other options (n ¼ 4). Ten companies indicated that risk indicators were first reviewed at the patient level either in terms of a defined percentage of enrolled patients or after a fixed time (screened/enrolled/treated). Eleven of 12 companies confirmed that at least some risk indicators were automatically calculated: 7 companies automatically calculated all of the risk indicators, 3 automatically calculated 75% of the risk indicators, and 1 automatically calculated 50% of the risk indicators.
There was no consensus across companies as to whether risk indicators were predictive of serious GCP and misconduct issues. Four companies indicated that risk indicators were predictive, whereas 6 responded that this information was unknown, and 2 reported that this was not the case. Of those that believed risk indicators were predictive of serious GCP and misconduct issues, adverse event and serious adverse event (AE and SAE) rates and data entry delay were referenced as specific examples.
Part 1 of the central monitoring paper described some differences in the functional models for central monitoring as implemented at TransCelerate member companies. 4 Early adopters tended to concentrate their efforts on phase 3 studies. Since then, with additional implementations, the landscape across study phases and types has expanded considerably ( Table 2) . With the exception of phase 1 trials, companies expressed an interest in expanding the scope of central monitoring across all types of trials in the future.
The TransCelerate RBM methodology states that various roles within different functional areas may be involved in central monitoring activities. 3, 4 TransCelerate member company survey results as presented in the ''People'' section of this paper indicate many (8 of 12) companies have adopted an approach that includes central monitors supporting efforts toward the central evaluation of site risks. Additionally, it was noted that a cohesive and cross-functional process for managing risk effectively should involve data management, statistics, clinical operations, and pharmacovigilance.
Implementation of central monitoring within companies was influenced by a variety of factors including audit findings and operational difficulty. Although cost of implementing was identified as a factor for 7 of 12 companies, only 5 of 12 companies evaluated return on investment (ROI) for central monitoring. Furthermore, opinions were divided as to the length of time it would take to offset the cost of setting up central monitoring (ranging from <1 year to >5 years), but this could be attributable to the diversity of operating models.
In terms of the impact of central monitoring on overall resources within a company, among the 12 respondents, 3 reported an increase in overall resources, 5 indicated no change, 2 confirmed a decrease, and 2 have not yet introduced central monitoring. There was no clear consistent determining factor in terms of the allocation of resources for central monitoring, but the number of trials and assignment of countries/ Response total is the number of companies who entered data for that study category; companies answered separately for each study type.
regions accounted for 12 of 29 responses (multiple choices per responder were possible). Although electronic data capture (EDC) is a vital data source for central monitoring, it was acknowledged that additional sources contribute to the central evaluation of aggregated data. These included, but were not limited to, site performance metrics, issue management, interactive response systems (such as those used for randomization or clinical drug shipment), and central laboratory data. The latter 2 sources accounted for 15 of the 29 responses.
Success Measures
TransCelerate member companies reported using several metrics to evaluate central monitoring including data quality, frequency of on-site visits, protocol deviations, SAE reporting rates, and site audit findings. It is too early to draw conclusions from the results of these metrics. Of the 12 companies that measured changes in the frequency of on-site monitoring, 6 noted a decrease attributed to the introduction of central monitoring activities. The magnitude of the decreases ranged from 20% to 40%.
Nine (>80%) of 11 companies using central monitoring reported that it has improved data quality as measured by their organizations. The 2 remaining companies confirmed that this information was unknown. Earlier issue identification and oversight of data added value by providing the ability to identify quality issues in real time and initiate targeted interventions in a timely manner. It was also reported that central monitoring facilitated an adaptive approach to monitoring, a focus on critical data, and the ability to support flexibility with on-site visit frequency. A reduction in the number of subjects lost to followup and consistency in the review and handling of noncompliance were also cited as benefits. Furthermore, 10 of 11 companies confirmed that central monitoring highlighted issues that would not have been found previously. Such issues included, but were not limited to, data quality outliers, trends in protocol deviations, early intervention for data query response time lag, and determination of clinical research associate (CRA) workload backlog.
Discussion and Conclusion
More than 2 years after the publication of the TransCelerate position paper on RBM, many of the TransCelerate member companies that have chosen to implement RBM have adapted monitoring practices to include central monitoring activities. As committed to in part 1 of this paper, 4 part 2 shares the lessons learned through this implementation.
The data included in this paper come from 2 separate surveys of TransCelerate member companies aware of, interested in, and engaged in this endeavor. However, there are acknowledged limitations to this approach. Inherent in the use of any survey is the potential lack of detail in responses and an inability to obtain further information. As with many surveys, there were several questions where further detail was desired, and the results generated additional questions not included in the survey. Although TransCelerate member companies are very knowledgeable in the practice of central monitoring, the sample size was small and caution should be taken in assuming responses are applicable outside this group. Further insights would likely be gained by broadening the pool of functions providing responses; however, we balanced that against requesting input from those unfamiliar with the application of RBM. Additionally, central monitoring, as proposed by TransCelerate, has only been implemented for a maximum of 2 years. Although a great deal of insight has been gained, there is limited experience in interactions with health authorities on these trials or in their use in regulatory submissions. This is a clear area of interest for all involved. With these identified limitations, survey data provide a valuable tool for understanding some of the common approaches used by member companies in the implementation of central monitoring and identify where stability of approach has not yet been achieved. It is hoped that by presenting these preliminary results of implementation, iteration toward a common approach can be facilitated.
A risk indicator library 9 was created with input from 12 contributing companies to determine perceived areas of risk where evaluation would bring the most value. Again, because of the newness of this model, stability does not yet exist. Risk indicators in the library need to be repeatedly used and their value measured over time. There is preliminary, largely anecdotal, evidence of value for several risk indicators and there is a high degree of commonality in the themes of risks worth assessing. This may be because some of the risk indicators are clear and have obvious value; thus, independent decisions to use these risk indicators (with variation in thresholds and configuration) are natural. The less common themes may be specific to the research of interest at any given company being distinct from that at other companies or because the less obvious areas of risk are identified differently across companies. Again, we hope to drive toward common approaches where appropriate. It is hoped that as technologies and methodologies evolve, new risk indicators will be identified to take advantage of these advances. As this model becomes more commonplace, it is also hoped that it will be easier to test new risk indicators to determine their utility in comparison with an already established set of common risk indicators.
Additionally, the risk indicator library provides a baseline for understanding what companies are currently using to conduct central monitoring and can serve as a starting point for companies who are new to RBM. The categories with the highest number of risk indicators are areas central to clinical operations and data management activities, further providing evidence of the focus of early adopters of TransCelerate's RBM recommendations. While this library represents a comprehensive list of risk indicators, it appears the preferred number of risk indicators in use on a given study is between 15 and 25. Methods to translate these risk indicators into a single, sufficiently sensitive, measure of relative site risk, in addition to the individual risk indicators, need further development and refinement and should be an area of further research. Additional guidance on the processes for choosing risk indicators and defining thresholds may also be required and should be considered for future work.
An area of particular interest for member companies has been the potential new role of the ''central monitor.'' As noted here, member companies have taken various approaches to organizational design to implement this capability. Not all companies have created a new role. Some have divided the key responsibilities among existing roles. However, it could be argued that effective implementation of the capability and activities of central monitoring requires a single process to assess risk, evaluate risk indicators, draw conclusions from these, and direct the resulting activity. This single process may be enabled most effectively by dedicated individuals.
The central monitoring tasks, as indicated in the survey results, contribute to a capability that is still immature in its development. As compared with a very mature capability such as site monitoring, defining the most effective central monitoring solutions is challenging and not yet well established in the marketplace. Key success factors to establishing central monitoring as a predictable capability include better definition on the knowledge and experience that best lends itself to success with these activities and availability of supporting technology. Member companies have highlighted skills that include an understanding of the identification and evaluation of risk as well as facility with analytical methods. Given that the roles involved are most frequently organizationally aligned with and recruited from Data Management and Clinical Operations, it seems clear that some background in one of these 2 disciplines is desired. An interesting result was the lack of identification of medical background as desirable for central monitors. Given the identification of medical review as a component of central monitoring, it is reasonable to expect this background to have been identified as a key requirement. It is possible that survey responders were too early in their central monitoring adoption to have embedded this definition into their thinking. It is also possible that the implementation of central monitoring has been accomplished in a phased approach at many companies where the medical review component, as a more nuanced and complex component, is not part of the initial adoption strategy. In any event, it is notable and worthy of further research to determine if any update in methodology is indicated based on the practicalities of implementing this part of central monitoring.
The results of the surveys indicate that the majority of TransCelerate member companies were accomplishing at least some of the monitoring of data away from sites through the use of a distinct role or via a combination of roles to review risk indicators in order to identify outliers and trends. Improvement in data quality was noted as a benefit of incorporating central monitoring as part of a comprehensive monitoring strategy, although it was not identified how this was measured or the magnitude of improvement. This belief appeared to be present regardless of the central monitoring model implemented. As noted earlier, organizational alignment of individuals conducting central monitoring tasks was identified as Data Management in at least half of the implementing companies but the need for cross-functional input was also identified.
Before a company makes the decision to embed central monitoring into a comprehensive monitoring strategy, the company should make sure of the following:
Well-defined processes exist for conducting monitoring away from sites. Enabling technologies, focused on the translation of data into information that can result in appropriate actions, are available.
It is clear what role(s) should be conducting central monitoring activities, and the skills and capabilities needed to be successful are well understood. Organization alignment for those conducting central monitoring activities has been established. The path from risk assessment to risk identification to risk management is clear and well understood. Well-defined critical success factors have been established for the implementation of central monitoring.
As regulatory guidance evolves and becomes increasingly prescriptive for RBM, adaptation and increased use of central monitoring activities will be a natural outcome. 8, 10, 11 Additional refinement of a robust set of metrics is needed to properly assess the benefits of implementation. The value of central monitoring and the pathway to predictability of the capability will be enabled by definition of, and alignment on, critical success factors. We encourage others, including the contract research organization (CRO) and vendor community, to publish on the success and failure of various operating models and technological advancements.
